- Home
- E vs EW Comparison
E vs EW Comparison
Compare E & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | E | EW |
|---|---|---|
| Founded | 1953 | 1958 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Industrial Specialties |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.0B | 45.5B |
| IPO Year | 1995 | 2000 |
Fundamental Metrics
Financial Performance| Metric | E | EW |
|---|---|---|
| Price | $37.77 | $86.87 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 20 |
| Target Price | $31.60 | ★ $95.83 |
| AVG Volume (30 Days) | 188.9K | ★ 3.1M |
| Earning Date | 10-24-2025 | 02-10-2026 |
| Dividend Yield | ★ 4.23% | N/A |
| EPS Growth | ★ 6.01 | N/A |
| EPS | 0.96 | ★ 2.33 |
| Revenue | ★ $101,555,790,226.00 | $5,883,800,000.00 |
| Revenue This Year | N/A | $14.29 |
| Revenue Next Year | N/A | $9.68 |
| P/E Ratio | ★ $18.57 | $37.04 |
| Revenue Growth | N/A | ★ 10.60 |
| 52 Week Low | $24.65 | $65.94 |
| 52 Week High | $38.47 | $87.89 |
Technical Indicators
Market Signals| Indicator | E | EW |
|---|---|---|
| Relative Strength Index (RSI) | 54.58 | 60.06 |
| Support Level | $37.58 | $85.79 |
| Resistance Level | $37.85 | $86.98 |
| Average True Range (ATR) | 0.33 | 1.55 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 88.15 | 95.71 |
Price Performance
Historical ComparisonAbout E ENI S.p.A.
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2024, the company produced 0.8 million barrels of liquids and 4.8 billion cubic feet of natural gas per day. At end-2024, Eni held reserves of 6.5 billion barrels of oil equivalent, 46% of which are liquids. The Italian government owns a 30.5% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity called Plenitude, which it will likely list publicly at some point.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.